VAXCHORA
Total Payments
$223,709
Transactions
37
Doctors
1
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $223,709 | 37 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $196,059 | 32 | 87.6% |
| Consulting Fee | $27,650 | 5 | 12.4% |
Payments by Type
Research
$196,059
32 transactions
General
$27,650
5 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| PXVX-VC-200 | Emergent BioSolutions Inc. | $141,863 | 0 |
| VAXCHORA Pediatric Study | Emergent BioSolutions Inc. | $54,196 | 0 |
Top Doctors Receiving Payments for VAXCHORA
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Boston, MA | $196,059 | 32 |
| , M.D | Pediatrics | Madera, CA | $27,650 | 5 |
Ad
Manufacturing Companies
- Emergent BioSolutions Inc. $223,709
Product Information
- Type Drug
- Total Payments $223,709
- Total Doctors 1
- Transactions 37
About VAXCHORA
VAXCHORA is a drug associated with $223,709 in payments to 1 healthcare providers, recorded across 37 transactions in the CMS Open Payments database. The primary manufacturer is Emergent BioSolutions Inc..
Payment data is available from 2019 to 2019. In 2019, $223,709 was paid across 37 transactions to 1 doctors.
The most common payment nature for VAXCHORA is "Unspecified" ($196,059, 87.6% of total).
VAXCHORA is associated with 2 research studies, including "PXVX-VC-200" ($141,863).